Viatris Inc. (NASDAQ:VTRS) Q1 2024 Earnings Call Transcript

Doretta Mistras: Yeah, so on emerging markets specifically, we were very pleased with the performance that we’ve seen in that region. It was really — we saw broad performance specifically both in our MENA and our Eurasia region, both across generics and across our branded portfolio such as Lipitor, Elidel, Xalabrands. So we really saw outperformance across the board. And this was despite some FX headwinds that we saw in that region. We had multiple currencies that we saw some weakness in versus the US dollar relative to last year. So we were very pleased with our performance in emerging markets. With respect to your second question around the divestitures, so yes, so as kind of the Women’s Health transaction we closed in March.

Given we expect to close the API transaction imminently, the way we’ve thought about the remainder of ’24, we’ve stripped out Women’s Health as of its close and we’ve stripped out the API business as if it has closed in May given its imminent closure — expected closure.

Operator: Thank you. And this concludes our question-and-answer session. I would like to return the conference to Mr. Scott Smith, CEO, for any closing comments.

Scott Smith: So thank you and thank you to everybody online for your attention this morning. In closing, we’re continuing our momentum for last year. We’ve had a great — we’ve made great progress on all our key priorities and have a strong executive leadership team in place, a passionate global workforce that’s dedicated to leading the company into what we believe is an exciting future ahead. Thank you again.

Operator: Thank you. The conference is now concluded. Thank you for attending today’s presentation. You may now disconnect your phone lines.